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Helodermin, anewly isolated peptide from the venom of Gila monster (Heloderma suspectum) was shown 
to stimulate the adenylate cyclase activity of rat pancreatic membranes a efficiently as secretin and VIP. 
It also increased cyclic AMP levels and inhibited [‘251]VIP binding in rat pancreatic acini. Finally, 
helodermin activated adenylate cyclase in membranes from rat heart, rat brain, and human heart, showing 
properties analogous yet distinct from those of secretin, VIP and PHI. 
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1. INTRODUCTION 
A new peptide, called helodermin, has been 
purified to homogeneity from the venom of 
Helodermina lizards, based on its capacity to 
stimulate rat pancreatic adenylate cyclase [ 11. Here 
we demonstrate that helodermin is able to: (i) 
stimulate, as efficiently as secretin and VIP, the 
adenylate cyclase activity of rat pancreatic plasma 
membranes; (ii) increase cyclic AMP levels and in- 
hibit [rz51]VIP binding competitively on dispersed 
rat pancreatic acini; and (iii) stimulate adenylate 
cyclase activity in membranes from rat heart, rat 
brain, and human heart differently from secretin, 
VIP and PHI. We conclude that helodermin is a 
member of the secretin/VIP/PHI family of pep- 
tides that exhibits a pattern of biological activities 
* To whom correspondence should be addressed 
Rat pancreatic acini were prepared and in- 
cubated as indicated in [3]. The acini were in- 
cubated at 37°C for 30 min. One ml cold ethanol 
was then added and the suspension was centrifuged 
for 30 min at 2000 x g. The supernatant was 
evaporated, and the residue was dissolved in 
0.05 M acetate buffer (pH 6.2). Cyclic AMP was 
determined using a cyclic AMP “‘1 RIA Kit (New 
England Nuclear, Dreieich). Under all conditions 
tested, cyclic AMP levels plateaued before 15 min. 
Abbreviations: VIP, vasoactive intestinal peptide; PHI, Binding of [12sI]VIP to pancreatic acini was per- 
peptide having an N-terminal histidine and a C-terminal formed as follows. [‘251]VIP was prepared as in [4] 
isoleucine amide and purified as in [5]. The radioactive ligand was 
analogous yet distinct from that of the 3 reference 
peptides. 
2. MATERIALS AND METHODS 
Helodermin was purified as in [l]. The molar 
peptide concentration was estimated by two con- 
verging techniques. The protein content determin- 
ed with the Folin reagent [2] assumed an Mr value 
of 5900. 
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added to the incubation medium enriched with 
0.1 mg/ml bacitracin with or without an unlabell- 
ed peptide. After 1 h, the incubation suspension 
was layered on di-n-butylphthalate. The acini were 
sedimented through the dense layer by a 15-s cen- 
trifugation. The microfuge tube was frozen in li- 
quid nitrogen and cut through the dense layer. The 
radioactivity in the lower part was counted in a 
gamma-counter. Non-specific binding referred to 
[“‘I]VIP bound in the presence of 1 PM VIP. 
Total binding never exceeded 10% of the tracer of- 
fered and non-specific binding amounted to 20% 
of total binding. 
Synthetic porcine secretin and secretin-(7-27) 
were generous gifts from Dr W. Konig (Hoechst 
Aktiengesellschaft, Frankfurt/Main). Synthetic 
VIP was purchased from UCB Bioproducts 
(Brussels). 
3. RESULTS 
3.1. Effects of heloderrnin on rat pancreatic 
preparations 
Rat pancreatic plasma membranes were 
prepared by two different methods. The first one 
was identical to that in [6], the second one was 
similar, except for the omission of 5 mM 
2-mercaptoethanol in all buffers used. It was 
verified that both methods gave identical profiles 
of membrane sedimentation. 
Rat brain synaptic membranes, rat heart mem- 
branes, and human heart membranes were 
prepared as in [7-91. 
Adenylate cyclase activity was determined as in 
[lo] as described in [l I]. Ten PM GTP was added 
systematically. Under all experimental conditions 
tested, the conversion of [~u-~~P]ATP into cyclic 
[32P]AMP was linear with time. 
Helodermin inhibited dose-dependently and 
competitively the binding of [1251]VIP to dispersed 
rat pancreatic acini. The peptide was 10 times less 
potent than unlabelled porcine VIP but 3 times 
more potent than porcine secretin (fig. 1, left 
panel). In the same type of preparation, VIP and 
secretin exerted distinct effects on cyclic AMP 
levels (fig.1, right panel). The relatively flat curve 
of VIP stimulation contrasted with the steeper 
curve of secretin and the maximum effect of VIP 
was significantly lower than that of secretin. The 
efficacy of helodermin on this parameter was com- 
parable to that of secretin but the potency of the 
peptide was 3 times lower than that of secretin. 
Adenylate cyclase activity in rat pancreatic 
membranes prepared in the presence (fig.2, left 
panel) or absence (fig.2, right panel) of 5 mM 
2-mer ca ptoethanol was differently stimulated by 
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Fig.1. Dose-effect curves of VIP (A), helodermin (0) and secretin (0) inhibition of [ 1z51]VIP binding (left panel) and 
cyclic AMP formation (right panel) in rat pancreatic acini. The results were representative of two other experiments. 
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Fig.2. Dose-effect curves of adenylate cyclase activation by secretin (O), VIP (A) and helodermin (0) in rat pancreatic 
plasma membranes prepared in the presence (left panel) or absence (right panel) of 5 mM 2-mercaptoethanol. The data 
were expressed in pmol cyclic AMP produced. min-’ . mg protein-’ and were representative of two other experiments. 
Basal activities were 23 and 43 pmol cyclic AMP. min-’ . mg protein-‘, respectively, in membranes prepared with and 
without 5 mM 2-mercaptoethanol. 
secretin, VIP, and helodermin. As compared to 
membranes prepared without 2-mercaptoethanol, 
those prepared in the presence of the reducing 
agent showed a lower specific activity of the en- 
zyme and, in addition, the sensitivity to secretin 
and helodermin was reduced lo-fold and that to 
VIP even further (200-fold). In this system, 
helodermin stimulation was, thus, more closely 
related to that of secretin than to that of VIP, 
although helodermin was 30-fold less potent than 
secretin. This hypothesis was further supported by 
the fact that secretin-(7-27), a secretin fragment 
previously reported to inhibit secretin effects com- 
petitively and selectively [I 1,121, was able to in- 
hibit dose-dependently the helodermin-stimulated 
adenylate cyclase activity (fig.3). Similar results 
were obtained with the crude venom tested under 
the same conditions [ 131. 
3.2. Effects of helodermin on adenylate cyclase 
activity in membranes from human heart, 
rat heart and rat brain 
Adenylate cyclase activity in human heart mem- 
branes was stimulated by VIP but not by secretin. 
Helodermin was more potent (Cfold) and more ef- 
ficient (by 25%) than VIP on this preparation 
(fig.4, left panel). In rat heart membranes, 
adenylate cyclase activity was stimulated by both 
secretin and VIP, although secretin was more po- 
tent and efficient than VIP. In this model, heloder- 
min appeared to be less potent but nearly as effi- 
cient as secretin (fig.4, middle panel). Adenylate 
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cyclase activity in rat brain membranes was 
stimulated by VIP but not by secretin, and 
helodermin proved to be almost as potent as VIP. 
4. DISCUSSION 
The crude venom from both Heloderma suspec- 
turn and Heloderma horridum contains a 
proteolytic-sensitive, thermostable component 
capable of interacting with VIP receptors in the .^_ 
[SECRETIN-(7-27) CONCENTRATION] (log M) 
Fig.3. Dose-effect curves of adenylate cyclase inhibition 
in the presence of increasing concentrations of 
secretin-(7-27), and in the presence of secretin (0), VIP 
(A), and helodermin (0). The experiments were 
performed on rat pancreatic membranes prepared in the 
absence of 2-mercaptoethanol. The concentrations of 
secretin (30 nM), VIP (0.3 PM), and helodermin 
(0.5 PM) used were able to stimulate adenylate cyclase 
maximally. The results were the mean of 2 experiments 
and were exnressed in % of enzyme activity in the 
- absence of secretin-(j-27). 
guinea pig pancreas as it inhibits [?]VIP binding 
to pancreatic acini, and stimulates cyclic AMP for- 
mation and amylase secretion [ 141. We recently 
presented evidence [13] that the crude venom 
stimulates adenylate cyclase through secretin- 
preferring rather than through VIP-preferring 
receptors, in rat pancreatic plasma membranes. 
The 5.9-kDa peptide component responsible for 
this effect has been purified to homogeneity by a 
method detailed in [I] and has been designated 
helodermin. 
Here, helodermin was shown to share some of 
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-8 -7 -6 -5 
I- 
-8 -7 -6 -5 -8 -7 -6 -5 
1 PEPTIDE CONCENTRATION] (log M ) 
75 
25 
120 
80 
VIP 
Helodermin 
Fig.4. Dose-effect curves of adenylate cyclase activation in presence of secretin (O), VIP (A) and helodermin (0) in 
human heart membranes (left panel), rat heart membranes (middle panel), and rat brain synaptic membranes (right 
panel). Data were expressed in pmol cyclic AMP produced * min-’ . mg protein-’ and were representative of 2 other 
experiments. Basal activities were, respectively, 22, 31 and 220 pmol cyclic AMP emin-‘. mg protein-’ for membranes 
from human heart, rat heart, and rat brain. 
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the properties of the crude venom: like VIP and 
secretin, it inhibited [1251]VIP binding and 
stimulated cyclic AMP accumulation in rat pan- 
creatic acini (fig.1); it also stimulated adenylate 
cyclase activity in rat pancreatic plasma mem- 
branes (fig.2). The affinity of helodermin for rat 
pancreatic VIP receptors was higher than that of 
secretin (fig. 1, left panel) but its action on rat pan- 
creatic cell membranes appeared, nevertheless, to 
be mediated through secretin receptors for 3 
reasons: 
(i) Dose-effect curves of helodermin and secretin 
on cyclic AMP formation in dispersed acini 
were comparable (fig. 1, right panel); 
(ii) Helodermin stimulation of adenylate cyclase 
activity, like that of secretin and at variance 
with that of VIP, was shifted only lo-fold to 
the right in pancreatic membranes prepared in 
the presence of 2-mercaptoethanol (fig.2); 
(iii) Helodermin effects were inhibited by 
secretin-(7-27), a specific marker of secretin 
receptors [ 11,121 (see fig.3). 
The fact that helodermin recognized rat pan- 
creatic secretin receptors suggests a structural rela- 
tionship of helodermin with the pig hormone. This 
conclusion was supported by the observation that 
helodermin was as efficient as secretin in 
stimulating adenylate cyclase activity in rat heart 
membranes (fig.4, middle panel), a system en- 
dowed with secretin-preferring receptors that 
recognize VIP only poorly [8]. 
Other helodermin activities were, however, 
distinct from those of secretin. The new peptide ac- 
tivated adenylate cyclase in rat brain membranes 
and human heart membranes as potently or even 
more potently than VIP (fig.4, left and right 
panels). These two models possess VIP-preferring 
receptors (with a relatively weak affinity for VIP) 
and are insensitive to secretin [9,12]. Helodermin 
was, thus, likely to interact with VIP receptors in 
these models although the existence of specific 
helodermin receptors cannot be definitively 
excluded. 
The interaction of helodermin with other recep- 
tor systems coupled with adenylate cyclase ap- 
peared unlikely: helodermin effects were not in- 
hibited by the ,&adrenergic antagonist propranolol 
on heart membranes, nor by the CCK-antagonist 
dibutyryl cyclic GMP on pancreatic plasma mem- 
branes (not shown). Helodermin differed also 
from PHI acting on VIP receptors [15]: PHI is, in- 
deed, less potent than VIP on human heart mem- 
branes [9] and less potent and efficient than VIP 
on rat heart membranes [16]. 
To conclude, helodermin appears to be a peptide 
related to secretin and VIP but with an original 
pattern of biological activities. Helodermin in- 
teracts with secretin or VIP receptors, depending 
on the system tested: its behavior is more secretin- 
like than VIP-like on secretin receptors but 
displays opposite affinities in the presence of VIP 
receptors. Of particular pharmacological interest is 
the fact that helodermin is a potent activator of 
human cardiac adenylate cyclase so that the pep- 
tide may, conceivably, be a better inotropic and 
chronotropic agent than VIP itself [17]. 
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